CY1108174T1 - Προληψη και θεραπεια της οστεοπορωσης που προκαλειται απο τη στερηση ανδρογονου - Google Patents

Προληψη και θεραπεια της οστεοπορωσης που προκαλειται απο τη στερηση ανδρογονου

Info

Publication number
CY1108174T1
CY1108174T1 CY20081100699T CY081100699T CY1108174T1 CY 1108174 T1 CY1108174 T1 CY 1108174T1 CY 20081100699 T CY20081100699 T CY 20081100699T CY 081100699 T CY081100699 T CY 081100699T CY 1108174 T1 CY1108174 T1 CY 1108174T1
Authority
CY
Cyprus
Prior art keywords
ostropornation
prevention
caused
treatment
androgen deprivation
Prior art date
Application number
CY20081100699T
Other languages
English (en)
Inventor
Mitchell S Steiner
Sharan Raghow
Karen A Veverka
Original Assignee
Gtx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtx, Inc. filed Critical Gtx, Inc.
Publication of CY1108174T1 publication Critical patent/CY1108174T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Abstract

Αυτή η εφεύρεση παρέχει 1) μία μέθοδο για την θεραπεία της οστεοπόρωσης που προκαλείται από τη στέρηση ανδρογόνου και/ή καταγμάτων οστού και/ή απώλειας της Πυκνότητας Ανόργανου Οστού (BMD) σε ένα αρσενικό υποκείμενο που υποφέρει από καρκίνο του προστάτη 2) μία μέθοδο για την πρόληψη της οστεοπόρωσης που προκαλείται από τη στέρηση ανδρογόνου και/ή καταγμάτων οστού και/ή απώλειας της Πυκνότητας Ανόργανου Οστού (BMD) σε ένα αρσενικό υποκείμενο που υποφέρει από καρκίνο του προστάτη 3) σε μία μέθοδο για την καταστολή ή αναστολή της οστεοπόρωσης που προκαλείται από τη στέρηση ανδρογόνου και/ή καταγμάτων οστού και/ή απώλειας της BMD σε ένα αρσενικό υποκείμενο που υποφέρει από καρκίνο του προστάτη 4) μία μέθοδο για την μείωση του κινδύνου ανάπτυξης της οστεοπόρωσης που προκαλείται από τη στέρηση ανδρογόνου και/ή καταγμάτων οστού και/ή απώλειας της BMD σε ένα αρσενικό υποκείμενο που υποφέρει από καρκίνο του προστάτη, μέσω της χορήγησης στο υποκείμενο μιας φαρμακευτικής σύνθεσης που περιλαμβάνει ένα παράγοντα αντι-οιστρογόνου και/ή ανάλογο του, παράγωγο, ισομερές, μεταβολίτη, φαρμακευτικώς αποδεκτό άλας, φαρμακευτικό προϊόν, υδρίτη, Ν-οξείδιο ή οποιοδήποτε συνδυασμό αυτών όπως περιγράφεται εδώ.
CY20081100699T 2001-11-29 2008-07-03 Προληψη και θεραπεια της οστεοπορωσης που προκαλειται απο τη στερηση ανδρογονου CY1108174T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33373401P 2001-11-29 2001-11-29
EP02804417A EP1460969B1 (en) 2001-11-29 2002-11-27 Prevention and treatment of androgen-deprivation induced osteoporosis

Publications (1)

Publication Number Publication Date
CY1108174T1 true CY1108174T1 (el) 2014-02-12

Family

ID=23304031

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20081100699T CY1108174T1 (el) 2001-11-29 2008-07-03 Προληψη και θεραπεια της οστεοπορωσης που προκαλειται απο τη στερηση ανδρογονου
CY20091100318T CY1108895T1 (el) 2001-11-29 2009-03-23 Προληψη και θεραπεια της οστεοπορωσης που προκαλειται απο τη στερηση ανδρογονου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20091100318T CY1108895T1 (el) 2001-11-29 2009-03-23 Προληψη και θεραπεια της οστεοπορωσης που προκαλειται απο τη στερηση ανδρογονου

Country Status (23)

Country Link
US (1) US6899888B2 (el)
EP (5) EP1666033B1 (el)
JP (2) JP2005515988A (el)
KR (1) KR100658110B1 (el)
CN (2) CN1679956A (el)
AT (2) ATE394099T1 (el)
AU (2) AU2002356928B2 (el)
BR (1) BR0214801A (el)
CA (2) CA2537913A1 (el)
CY (2) CY1108174T1 (el)
DE (2) DE60226494D1 (el)
DK (2) DK1666033T3 (el)
EA (1) EA200400744A1 (el)
ES (2) ES2319785T3 (el)
GE (1) GEP20094841B (el)
HK (2) HK1068104A1 (el)
HR (1) HRP20040547A2 (el)
IL (2) IL162144A0 (el)
MX (1) MXPA04005112A (el)
PT (2) PT1666033E (el)
SI (2) SI1666033T1 (el)
TW (1) TWI315987B (el)
WO (1) WO2003047504A2 (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7622503B2 (en) * 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof
CA2578852A1 (en) * 2004-09-03 2006-03-09 Hormos Medical Corporation Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
AU2006339325A1 (en) * 2005-11-09 2007-09-07 Hormos Medical Ltd. Formulations of fispemifene
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
EA201500845A1 (ru) * 2005-11-28 2016-04-29 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
CN101636372B (zh) 2007-02-14 2013-03-27 霍尔莫斯医疗有限公司 有治疗价值的三苯基丁烯衍生物的制备方法
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
CA2709677C (en) * 2007-12-21 2017-03-14 Lin Zhi Selective androgen receptor modulators (sarms) and uses thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
DK2872482T3 (da) 2012-07-13 2020-09-21 Oncternal Therapeutics Inc En fremgangsmåde til behandling af brystkræft med selektiv androgenreceptormodulator (sarm)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
KR20170040797A (ko) * 2014-07-24 2017-04-13 아스펜 파크 파마슈티컬스 인코포레이티드 시스-클로미펜을 이용하여 안드로겐 박탈 요법 유발된 일과성 열감 및 골 소실을 치료하는 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2464203A (en) 1943-05-21 1949-03-15 Boots Pure Drug Co Ltd Manufacture of dienoestrol
US2465505A (en) 1944-12-05 1949-03-29 Hoffmann La Roche Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4
US2914562A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethanol
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE69034035T2 (de) * 1989-07-07 2004-01-22 Endorecherche Inc., Ste-Foy Methode zur behandlung androgenbedingter krankheiten
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5468488A (en) * 1993-06-24 1995-11-21 Wahi; Ashok L. Electrostatically charged nasal application product and method
TW303299B (el) * 1993-07-22 1997-04-21 Lilly Co Eli
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US5859045A (en) * 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6410043B1 (en) 1998-05-07 2002-06-25 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
SI1003496T1 (en) 1998-05-07 2005-10-31 The University Of Tennessee Research Corporation Medicament for treating prostate intraepithelial neoplasia
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
JP2002518328A (ja) * 1998-06-16 2002-06-25 ファイザー・プロダクツ・インク 筋骨格虚弱の治療用の（選択的）エストロゲン受容体モジュレーター（ｓｅｒｍ）および成長ホルモン分泌促進薬（ｇｈｓ）の治療的組合せ
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
ES2255294T3 (es) * 1998-08-07 2006-06-16 Chiron Corporation Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos.
AU5144999A (en) * 1998-08-07 2000-02-28 Endorecherche Inc. Inhibition of type 3 3alpha-hydroxysteroid dehydrogenase
EP1187618A1 (en) * 1999-06-04 2002-03-20 The General Hospital Corporation Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
KR20020075388A (ko) * 1999-12-30 2002-10-04 시그널 파머슈티컬스 인크 에스트로겐 수용체의 조절 화합물 및 조절 방법
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
EP1324754A1 (en) * 2000-07-05 2003-07-09 AstraZeneca AB Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition

Also Published As

Publication number Publication date
CN1617691A (zh) 2005-05-18
CA2537913A1 (en) 2003-06-12
ES2319785T3 (es) 2009-05-12
WO2003047504A2 (en) 2003-06-12
US20030153625A1 (en) 2003-08-14
EP2098247A3 (en) 2010-05-26
CA2468719A1 (en) 2003-06-12
EP1460969A4 (en) 2005-08-17
HK1068104A1 (en) 2005-04-22
AU2002356928A1 (en) 2003-06-17
IL162144A0 (en) 2005-11-20
EP1862165A2 (en) 2007-12-05
TWI315987B (en) 2009-10-21
DK1666033T3 (da) 2009-04-06
GEP20094841B (en) 2009-11-25
MXPA04005112A (es) 2005-04-29
CN1679956A (zh) 2005-10-12
EP1460969B1 (en) 2008-05-07
EP1862165A3 (en) 2008-06-25
EP1666033A1 (en) 2006-06-07
EP1460969A2 (en) 2004-09-29
US6899888B2 (en) 2005-05-31
BR0214801A (pt) 2005-01-11
ES2305350T3 (es) 2008-11-01
CA2468719C (en) 2011-05-24
AU2002356928B2 (en) 2008-04-17
DE60226494D1 (de) 2008-06-19
SI1460969T1 (sl) 2008-10-31
IL206646A0 (en) 2011-07-31
EP2098247A2 (en) 2009-09-09
WO2003047504A3 (en) 2003-10-16
ATE418972T1 (de) 2009-01-15
DK1460969T3 (da) 2008-09-01
EP1574212A1 (en) 2005-09-14
JP2005515988A (ja) 2005-06-02
CY1108895T1 (el) 2014-07-02
JP2005247862A (ja) 2005-09-15
AU2008203121A1 (en) 2008-08-07
KR100658110B1 (ko) 2006-12-14
HK1092066A1 (en) 2007-02-02
PT1666033E (pt) 2009-02-09
CN100548283C (zh) 2009-10-14
ATE394099T1 (de) 2008-05-15
HRP20040547A2 (en) 2005-08-31
DE60230687D1 (de) 2009-02-12
EA200400744A1 (ru) 2005-02-24
KR20050044618A (ko) 2005-05-12
PT1460969E (pt) 2008-07-01
TW200410711A (en) 2004-07-01
SI1666033T1 (sl) 2009-06-30
EP1666033B1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
CY1108895T1 (el) Προληψη και θεραπεια της οστεοπορωσης που προκαλειται απο τη στερηση ανδρογονου
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
SE9901272D0 (sv) New improved formulation
AU6147401A (en) Compositions and methods for the treatment of cancer
EP1446114A4 (en) COMPOSITIONS AND METHODS FOR TREATING OSTEOPOROSIS
HK1068551A1 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
EP1379242A4 (en) METHOD OF TREATING CANCERS AND APPROPRIATE COMPOSITIONS
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
IL145397A0 (en) Compositions and methods for treatment of cancer
NO20024735D0 (no) Anvendelse av fulvestrant for behandling av resistent brystcancer
PL368035A1 (en) Compositions and methods for the treatment of cancer
EP1576113A4 (en) TUMOR ANTIGENS BFA4 AND BCY1 FOR PREVENTING AND / OR TREATING CANCER
IL160816A0 (en) Compositions and methods for treatment of cancer
DK1379242T3 (da) Fremgangsmåde til behandling af cancer og sammensætninger til anvendelse derved
EP1379538A4 (en) RIBOZYMES INHIBITING ACE EXPRESSION AND METHODS OF TREATING CANCER BASED ON THESE RIBOZYMES